Viking Therapeutics Shares Plummet Following Clinical Trial Data Release

Shares of Viking Therapeutics experienced a dramatic sell-off after the biopharmaceutical company released Phase 2 trial results for its oral weight-loss drug candidate, VK2735. The stock plummeted approximately 34% as investors digested the complex data set.

While the study demonstrated impressive efficacy—with the highest dose group achieving an average weight reduction of 12.2% in just 13 weeks—concerns over patient discontinuation rates and gastrointestinal side effects overshadowed these positive results. This adverse reaction prompted a significant market reassessment of the drug’s commercial potential.

Key Trial Outcomes and Market Context

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Market experts noted that the speed of weight loss observed with VK2735 is notable, especially when compared to the timeframes required for competing therapies to achieve similar results. The company suggested that optimizing dosage levels over extended treatment periods could potentially mitigate the side effect profile that alarmed investors.

• Efficacy Data: Participants receiving the highest oral dose of VK2735 saw a mean weight loss of 12.2% over a three-month period.
• Competitive Landscape: Viking is challenging industry heavyweights Eli Lilly and Novo Nordisk, which currently control the lucrative obesity drug market.
• Pipeline Diversification: Beyond the oral formulation, Viking is also advancing an injectable version of VK2735, which is now in Phase 3 trials, and another compound, VK2809, targeting metabolic liver diseases.

The intense scrutiny on Viking’s data underscores the high-stakes nature of the biotech sector, where emerging companies must prove they can compete with established giants. The market’s reaction reflects a cautious approach, weighing strong efficacy signals against safety and tolerability concerns before confirming a drug’s ultimate viability.